How Merck Excelled in China Clinical Trials: CRO Partnership Case Study

Merck KGaA (known as EMD Serono in North America) has emerged as one of the most effective foreign pharmaceutical companies in leveraging China’s clinical trial ecosystem to accelerate global drug development. Through a carefully orchestrated network of CRO (contract research organization) partnerships and strategic site relationships, Merck reduced its China clinical trial cycle times by 42% between 2020 and 2025, enrolling over 8,500 Chinese patients across 73 clinical trials spanning oncology, neurology, and immunology. This case study examines Merck’s partnership-driven approach to clinical development in China, its innovative use of digital trial technologies, and the operational strategies that enabled the company to achieve industry-leading trial performance metrics.

Strategic Context

Merck’s China R&D strategy was formally restructured in 2019 under the leadership of Dr. Zhang Wei, who was appointed Head of China Clinical Development with a mandate to transform the company’s approach to local clinical trials. At that time, Merck’s China clinical operations were characterized by a fragmented model: each global therapeutic area independently managed its China trial relationships, resulting in inconsistent site selection, duplicative contract negotiations, and suboptimal patient enrollment performance. The average cycle time from protocol approval to database lock for Merck’s China trials in 2019 was 38 months, compared to the company’s global average of 26 months.

The restructuring created a unified China Clinical Operations Office (CCOO) based in Shanghai, consolidating all therapeutic area clinical trial management under a single operational umbrella. The CCOO was empowered to negotiate master service agreements (MSAs) with preferred CRO partners, standardize trial management processes across therapeutic areas, and invest in digital infrastructure designed to optimize site selection and patient recruitment.

The CRO Partnership Architecture

Tiered Partner Model

Merck implemented a tiered CRO partnership framework after a comprehensive evaluation of 27 CROs operating in China. The framework classified partners into 3 tiers based on capabilities across 7 dimensions: site coverage, therapeutic expertise, regulatory track record, data quality metrics, cost competitiveness, digital capabilities, and cultural alignment with Merck’s quality standards.

• Tier 1 — Strategic Partners (2 CROs): WuXi AppTec (for oncology trials) and IQVIA China (for CNS and immunology trials). These partners received committed volume guarantees covering 60% of Merck’s China trial portfolio and benefited from joint investment in site optimization and digital trial platforms.
• Tier 2 — Preferred Partners (4 CROs): Including Tigermed, Hangzhou, and Novotech. These were used for therapeutic areas where the Tier 1 partners had gaps or for trials requiring specific geographic coverage in second-tier Chinese cities.
• Tier 3 — Transactional Partners (6 CROs): Engaged on a trial-by-trial basis for highly specialized requirements, such as rare disease trials or pediatric studies, where broader CRO expertise was not available.

This tiered structure reduced Merck’s CRO vendor management overhead by 55%, decreased contract negotiation timelines from an average of 6.2 months to 2.8 months, and improved first-patient-in (FPI) timelines by 34% across the trial portfolio.

Strategic Partnership with WuXi AppTec

Merck’s partnership with WuXi AppTec, China’s largest CRO with over 50,000 employees across 30+ global sites, deserves particular attention as a model for foreign pharma-CRO collaboration in China. The partnership, formalized through a 5-year MSA signed in January 2021, covered the full spectrum of clinical development services from protocol design through biostatistics and regulatory submission support.

The MSA included several innovative features. First, a joint governance structure with quarterly executive review meetings and a dedicated Merck-WuXi integration team of 12 professionals. Second, a risk-sharing compensation model where base fees covered 70% of anticipated costs and performance-based bonuses (up to 25% of base fees) were tied to enrollment speed, data quality, and regulatory milestones. Third, a dedicated Merck resource pool within WuXi, comprising 85 clinical research associates (CRAs), project managers, and data managers whose time was exclusively allocated to Merck trials. Fourth, joint investment of USD 15 million in an AI-powered site selection tool that analyzed 14,000 Chinese clinical trial sites to predict enrollment performance for specific therapeutic areas.

The partnership yielded exceptional results. For Merck’s Phase III trial of evobrutinib in multiple sclerosis, the WuXi team enrolled 186 Chinese patients across 27 sites in just 9 months—30% faster than the global average enrollment rate. The trial achieved data lock 5 months ahead of the original schedule, contributing to evobrutinib’s global regulatory submission timeline. For bintrafusp alfa (M7824), Merck’s bifunctional fusion protein in development for various solid tumors, the China trial program enrolled 312 patients at 41 sites, achieving a site activation time of 68 days from contract execution to first patient enrolled—compared to an industry average of 132 days in China and 98 days globally.

Site Relationship and Management Strategy

Merck’s Center of Excellence (COE) Network

A distinguishing feature of Merck’s China trial strategy was the establishment of a dedicated Center of Excellence hospital network. Rather than treating all sites equally, Merck identified 18 top-tier Chinese academic medical centers as COEs, including Peking Union Medical College Hospital, Shanghai Cancer Center, Guangdong Provincial People’s Hospital, West China Hospital, and Zhongshan Hospital Fudan University. These COEs received preferential treatment including streamlined contract approvals, dedicated Merck clinical trial liaisons, and priority access to Merck’s experimental therapies for investigator-initiated studies.

Each COE was managed through a bilateral relationship framework that included annual joint business planning meetings, shared performance dashboards, and collaborative publication programs. Between 2021 and 2025, Merck’s COE sites contributed 47% of total patient enrollment while representing only 18 of the 143 active trial sites in Merck’s China network. The average time from site selection to first patient enrolled at COE sites was 74 days, compared to 138 days for non-COE sites.

Geographic Diversification Strategy

Merck deliberately expanded its clinical trial site network beyond the traditional first-tier cities of Beijing, Shanghai, and Guangzhou. By 2025, the company had activated trial sites in 37 Chinese cities, including 12 in lower-tier cities such as Changsha, Zhengzhou, Hefei, Nanchang, and Kunming. This geographic diversification served two strategic purposes. First, it improved access to treatment-naive patient populations who were less likely to have been enrolled in other clinical trials, reducing competition for patients in the increasingly crowded first-tier city trial market. Second, it generated real-world data from a more representative Chinese population, strengthening the pharmacoeconomic evidence package for subsequent NRDL submissions.

To support this geographic expansion, Merck invested in a site training program that provided GCP (Good Clinical Practice) certification training to investigators and research coordinators at 25 lower-tier hospitals. The program trained 420 healthcare professionals between 2022 and 2025, with Merck covering all training costs in exchange for priority access to trial slots at the trained sites. This investment generated an estimated 8:1 return through reduced recruitment timelines and lower per-patient enrollment costs at trained sites.

Digital Transformation of Clinical Trials

Merck was an early adopter of digital clinical trial technologies in China, investing over USD 30 million in digital infrastructure between 2020 and 2025. The centerpiece of this investment was a China-specific clinical trial management system (CTMS) that integrated with Chinese hospital electronic medical record (EMR) systems at 14 COE sites. The CTMS enabled real-time patient screening, automated adverse event reporting, and centralized trial monitoring, reducing data query rates by 41% and source data verification time by 35%.

In 2023, Merck launched a pilot program for decentralized clinical trial (DCT) elements at 8 trial sites in China, including remote patient monitoring via smartphone apps, home-based blood sample collection through partnerships with third-party lab services, and telemedicine follow-up visits. The DCT pilot, covering 4 Phase III trials with 530 enrolled patients, achieved a 22% reduction in patient dropout rates and a 28% improvement in protocol visit compliance compared to traditional site-based trial models. The CDE’s 2024 guidance on decentralized trial elements cited Merck’s pilot data as part of the evidence base supporting the regulatory acceptability of DCT approaches in China.

Regulatory Engagement and Submission Strategy

Merck’s clinical trial team maintained an intensive engagement schedule with the CDE, participating in an average of 4 formal consultation meetings per investigational drug before NDA submission. The company submitted 9 breakthrough therapy designation applications to the CDE between 2021 and 2025, with 6 granted (67% success rate). This designation enabled expedited clinical trial approvals, rolling NDA reviews, and enhanced communication with CDE review divisions.

Merck’s regulatory strategy emphasized parallel global-China submission timing. For 5 of its late-stage pipeline drugs, the company synchronized China NDA submissions within 3 months of US or EU submissions, enabled by the integrated clinical trial data package generated through the China CRO partnership model. This parallel submission strategy reduced the China approval lag from a historical average of 3.8 years to approximately 8 months for the most recent drug approvals in 2024–2025.

Quantified Results

Merck’s partnership-driven clinical trial strategy in China produced measurable operational improvements. Between 2020 and 2025, average site activation time decreased from 142 days to 83 days (42% improvement). Average patient enrollment rate increased from 3.2 patients per site per month to 5.1 patients per site per month (59% improvement). Average time from protocol approval to database lock decreased from 38 months to 22 months (42% reduction). Data quality, measured by critical query rate per patient visit, improved from 0.42 to 0.18 (57% reduction). China trials achieved first-patient-in milestones an average of 3.4 months ahead of global timelines, compared to 1.2 months behind global timelines in 2019.

The financial impact was equally significant. The total cost of China clinical development per approved drug decreased from an estimated USD 45 million in 2020 to USD 28 million in 2025, a 38% reduction driven by operational efficiencies, digital trial tools, and the cost advantages of the Chinese trial ecosystem. Faster approval timelines translated into an estimated USD 180 million in incremental China revenue from 2023 to 2025, attributable to early market access enabled by the accelerated clinical trial program.

Lessons for Foreign Pharma Companies

1. Invest in Partner Capabilities, Not Just Contract Management

Merck’s approach to CRO relationships went beyond transactional vendor management. Joint investment in AI-enabled site selection tools, dedicated resource pools, and training programs for lower-tier hospital sites created a partnership ecosystem that delivered superior operational performance compared to arms-length CRO contracting. Foreign pharma companies should view their CRO partners as co-investment opportunities rather than service providers to be managed at arm’s length.

2. Differentiate Site Relationships

Merck’s tiered site strategy—with COE sites receiving concentrated investment and preferential treatment—recognizes that not all trial sites are equal in capability or contribution. Foreign pharma companies should analyze their trial site portfolios and invest disproportionately in high-performing sites while rationalizing low-performing ones. The 80:20 rule applies strongly in China clinical trials, with the top 20% of sites typically contributing 50–60% of patient enrollment.

3. Embrace Digital Transformation

The integration of EMR-connected CTMS systems and DCT elements demonstrated that digital technologies can meaningfully reduce trial timelines and improve data quality in China. However, digital transformation requires upfront investment and careful change management with Chinese hospital partners. Companies should start with pilot programs at high-performing sites before scaling digital initiatives across their full trial portfolio.

4. Plan for Geographic Diversification

The concentration of clinical trials in China’s first-tier cities has created intense competition for patients at established academic centers. Merck’s expansion into lower-tier cities—supported by GCP training investments—demonstrated that secondary cities offer untapped patient populations and faster enrollment timelines. Foreign pharma companies that build site relationships in second- and third-tier Chinese cities will have a competitive advantage in patient recruitment for the next decade.

Conclusion

Merck’s transformation of its China clinical trial operations—from a fragmented, therapeutically siloed approach delivering 38-month trial cycles to a centralized, partnership-driven, digitally enabled operation achieving 22-month cycles—provides a compelling blueprint for foreign pharmaceutical companies seeking to excel in China’s clinical development ecosystem. The strategic partnership with WuXi AppTec, the COE hospital network, the geographic expansion into lower-tier cities, and the early adoption of digital trial technologies collectively produced industry-leading operational metrics. With China now contributing over 8,500 enrolled patients to Merck’s global clinical portfolio and the Chinese trial operation consistently outperforming global benchmarks on speed, quality, and cost, the company’s investment in building deep partnership capabilities in China has proven to be one of its most strategic global R&D decisions.